1,326
Views
1
CrossRef citations to date
0
Altmetric
Coronavirus – Case Report

SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Article: 2101334 | Received 13 Apr 2022, Accepted 09 Jul 2022, Published online: 01 Aug 2022

References

  • Han Z, Battaglia F, Terlecky SR. Discharged COVID-19 patients testing positive again for SARS-CoV-2 RNA: a minireview of published studies from China. J Med Virol. 2021;93(1):1–5. doi:10.1002/jmv.26250.
  • Dao TL, Hoang VT, Gautret P. Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review. Eur J Clin Microbiol Infect Dis. 2021;40(1):13–25. doi:10.1007/s10096-020-04088-z.
  • Ikegami S, Benirschke R, Flanagan T, Tanna N, Klein T, Elue R, Debosz P, Mallek J, Wright G, Guariglia P, Kang J. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors. J Med Virol. 2020;92(11):2366–2367. doi:10.1002/jmv.26056.
  • Kang H, Wang Y, Tong Z, Liu X. Retest positive for SARS-CoV-2 RNA of “recovered” patients with COVID-19: persistence, sampling issues, or re-infection? J Med Virol. 2020;92(11):2263–2265. doi:10.1002/jmv.26114.
  • Stanevich O, Alekseeva E, Sergeeva M, Fadeev A, Komissarova K, Ivanova A, Simakova T, Vasilyev K, Shurygina AP, Stukova M, et al. SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19. Researchsquare. Version 1, Posted28 Jul, 2021. doi:10.21203/rs.3.rs-750741/v1.
  • Avouac J, Drumez E, Seror R, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Marotte H, Servettaz A, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3(6):e419–e426. doi:10.1016/S2665-9913(21)00059-X.
  • Jin H, Reed JC, Liu ST, Ho HE, Lopes JP, Ramsey NB, Waqar O, Rahman F, Aberg JA, Bouvier NM, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract. 2020;8(10):3594–3596.e3. doi:10.1016/j.jaip.2020.08.059.
  • Hueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, Chatenoud L, Eshagh D, Szwebel TA, Martinot M, Camou F. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–2295. doi:10.1182/blood.2020008423.
  • Turakhia Y, Thornlow B, Hinrichs AS, De Maio N, Gozashti L, Lanfear R, Haussler D, Corbett-Detig R. Ultrafast sample placement on existing tRees (UShER) enables real-time phylogenetics for the SARS-CoV-2 pandemic. Nat Genet. 2021;53(6):809–816. doi:10.1038/s41588-021-00862-7.
  • Marty R, Kaabinejadian S, Rossell D, Slifker MJ, van de Haar J, Engin HB, de Prisco N, Ideker T, Hildebrand WH, Font-Burgada J, et al. MHC-I genotype restricts the oncogenic mutational landscape. Cell. 2017;171(6):1272–1283.e15. doi:10.1016/j.cell.2017.09.050.
  • Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMhcpan-4.1 and NetMhciipan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):W449–W454. doi:10.1093/nar/gkaa379.
  • Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, Wheeler DK, Sette A, Peters B. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 2019;47(D1):D339–D343. doi:10.1093/nar/gky1006.
  • Behloul N, Baha S, Shi R, Meng J. Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein. Virus Res. 2020;286:198058. doi:10.1016/j.virusres.2020.198058.
  • Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med. 2021;385(6):562–566. PMID: 34347959; PMCID: PMC8494465. doi:10.1056/NEJMsb2104756.
  • Nyström K, Hjorth M, Fust R, Nilsdotter-Augustinsson Å, Larsson M, Niward K, Nyström S. Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report. BMC Infect Dis. 2022;22(1):362. PMID: 35410137; PMCID: PMC8996199. doi:10.1186/s12879-022-07323-4.
  • Hueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, Chatenoud L, Eshagh D, Szwebel TA, Martinot M, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–2295. PMID: 32959052; PMCID: PMC7702482. doi:10.1182/blood.2020008423.
  • London J, Boutboul D, Lacombe K, Pirenne F, Heym B, Zeller V, Baudet A, Ouedrani A, Bérezné A. Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy. J Clin Immunol. 2021;41(2):356–361. Epub 2020 Nov 20. PMID: 33219491; PMCID: PMC7678568. doi:10.1007/s10875-020-00904-5.
  • Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J, Bowman K, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383(23):2291–2293. Epub 2020 Nov 11. PMID: 33176080; PMCID: PMC7673303. doi:10.1056/NEJMc2031364.